Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

 

Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019
A

Waldenstrom's Macroglobulinemia - Novel Agents in Initial Treatment, Venetoclax in R/R Disease & Impact of Mutation Status

By Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019 FEATURING Anuj Mahindra
By Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019 FEATURING Anuj Mahindra
1,120 views
September 4, 2019
0 Comments
Login to view comments. Click here to Login
Malignant Hematology
13:11
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Waldenstrom's Macroglobulinemia - Novel Agents in Initial Treat…

Feat. A. Mahindra
26:26
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Novel Treatment Options for AL & ATTR Amyloidosis

Feat. A. Mahindra
17:11
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

First Line Treatment for CLL - Ibrutinib Plus Obinutuzumab, Ibrutini…

Feat. W. Wierda
13:01
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Future Standard of Care Regimens in CLL: Ibrutinib + Venetoclax Comb…

Feat. W. Wierda
09:20
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Treatment for Relapsed/Refractory CLL - Updates from MURANO Trial (V…

Feat. W. Wierda
10:01
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Primary CNS Lymphoma - Clinical Features & Staging, Pretreatment…

Feat. C. Grommes
13:27
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Treatment of Primary CNS Lymphoma: Upfront Regimen, Surgery, Treatme…

Feat. C. Grommes
13:57
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Targeted Therapies in CNS Lymphoma & Salvage Options per NCCN Gu…

Feat. C. Grommes
09:16
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

AML and CD33 Targeted Therapy - Results from Gemtuzumab Ozogamicin T…

Feat. A. Perl
08:56
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Novel Treatment Options for High-Risk/Eldery AML Patients: CPX-351, …

Feat. A. Perl
18:23
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Targeting FLT3 mutations in AML: Daunorubicin, Midostaurin, Sorafeni…

Feat. A. Perl
06:37
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Targeting IDH Inhibitors in AML with Enasidenib and Ivosidenib

Feat. A. Perl
32:01
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Frontline Treatment Options for Hodgkin's Lymphoma: Response-Ad…

Feat. J. Svoboda
15:22
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Relapsed/Refractory Hodgkin Lymphoma - Salvage Treatments, Nivolumab…

Feat. J. Svoboda
22:03
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Frontline Strategy for Aggressive Lymphoma - Can we Replace RCHOP?

Feat. J. Westin
23:24
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Treatment of Relapsed Aggressive Lymphoma - Evaluating CAR T Trials

Feat. J. Westin
09:49
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Overview of Diagnosis and Prognosis in Pediatric vs. Adult ALL

Feat. H. Kantarjian
16:17
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

Pediatric Inspired Regimens in Adult ALL: Is Combination Therapy Bet…

Feat. H. Kantarjian
21:08
Scripps Cancer Center's 39th Annual Conference: Clinical Hematology & Oncology 2019

MRD-Positive ALL Treatment Options in 2019: Antibody Cocktail Regime…

Feat. H. Kantarjian